Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 14878 | 4.49 |
09:34 ET | 9781 | 4.52 |
09:36 ET | 3380 | 4.49 |
09:38 ET | 3323 | 4.46 |
09:39 ET | 2200 | 4.43 |
09:41 ET | 5805 | 4.455 |
09:43 ET | 1401 | 4.482 |
09:45 ET | 3341 | 4.405 |
09:48 ET | 3474 | 4.405 |
09:50 ET | 3988 | 4.385 |
09:52 ET | 2561 | 4.415 |
09:54 ET | 3138 | 4.405 |
09:56 ET | 933 | 4.415 |
09:57 ET | 1242 | 4.41 |
09:59 ET | 2217 | 4.43 |
10:01 ET | 2000 | 4.405 |
10:03 ET | 200 | 4.405 |
10:06 ET | 5122 | 4.43 |
10:08 ET | 900 | 4.435 |
10:10 ET | 1208 | 4.425 |
10:12 ET | 1534 | 4.405 |
10:14 ET | 430 | 4.41 |
10:15 ET | 600 | 4.4101 |
10:19 ET | 1414 | 4.405 |
10:21 ET | 100 | 4.405 |
10:24 ET | 5513 | 4.45 |
10:26 ET | 1216 | 4.44 |
10:28 ET | 2107 | 4.43 |
10:30 ET | 600 | 4.435 |
10:32 ET | 8461 | 4.435 |
10:33 ET | 1961 | 4.41 |
10:35 ET | 3762 | 4.406 |
10:37 ET | 1068 | 4.405 |
10:39 ET | 800 | 4.4093 |
10:42 ET | 2169 | 4.4025 |
10:44 ET | 2444 | 4.38 |
10:46 ET | 870 | 4.385 |
10:48 ET | 1880 | 4.3725 |
10:50 ET | 2473 | 4.38 |
10:51 ET | 300 | 4.375 |
10:53 ET | 933 | 4.365 |
10:55 ET | 7744 | 4.345 |
10:57 ET | 200 | 4.35 |
11:00 ET | 563 | 4.35 |
11:02 ET | 2861 | 4.322 |
11:04 ET | 1350 | 4.3388 |
11:06 ET | 4422 | 4.345 |
11:08 ET | 2247 | 4.36 |
11:09 ET | 326 | 4.35 |
11:11 ET | 1076 | 4.345 |
11:13 ET | 1700 | 4.33 |
11:15 ET | 800 | 4.35 |
11:18 ET | 550 | 4.34 |
11:20 ET | 1200 | 4.355 |
11:22 ET | 3052 | 4.35 |
11:24 ET | 3272 | 4.345 |
11:26 ET | 2900 | 4.345 |
11:27 ET | 9145 | 4.37 |
11:29 ET | 2024 | 4.375 |
11:31 ET | 1800 | 4.39 |
11:33 ET | 4626 | 4.385 |
11:36 ET | 4400 | 4.3926 |
11:38 ET | 7521 | 4.381 |
11:40 ET | 900 | 4.38 |
11:42 ET | 1925 | 4.38 |
11:44 ET | 500 | 4.39 |
11:45 ET | 2580 | 4.3862 |
11:47 ET | 2500 | 4.4 |
11:49 ET | 988 | 4.3911 |
11:51 ET | 3900 | 4.41 |
11:54 ET | 9742 | 4.435 |
11:56 ET | 66427 | 4.3999 |
11:58 ET | 1181 | 4.39 |
12:00 ET | 500 | 4.385 |
12:02 ET | 2110 | 4.37 |
12:03 ET | 3760 | 4.385 |
12:05 ET | 1700 | 4.395 |
12:07 ET | 200 | 4.4 |
12:09 ET | 5260 | 4.375 |
12:12 ET | 25464 | 4.4199 |
12:14 ET | 12111 | 4.4 |
12:16 ET | 17383 | 4.405 |
12:18 ET | 4278 | 4.405 |
12:20 ET | 17712 | 4.3886 |
12:21 ET | 5625 | 4.4194 |
12:23 ET | 1500 | 4.42 |
12:25 ET | 3628 | 4.42 |
12:27 ET | 5850 | 4.415 |
12:30 ET | 1900 | 4.415 |
12:32 ET | 1503 | 4.425 |
12:34 ET | 1947 | 4.41 |
12:36 ET | 2445 | 4.43 |
12:38 ET | 700 | 4.44 |
12:39 ET | 1592 | 4.44 |
12:41 ET | 6085 | 4.45 |
12:43 ET | 111156 | 4.445 |
12:45 ET | 13286 | 4.45 |
12:48 ET | 6988 | 4.44 |
12:50 ET | 1097 | 4.4335 |
12:52 ET | 2183 | 4.46 |
12:56 ET | 1372 | 4.46 |
12:57 ET | 10723 | 4.445 |
12:59 ET | 3100 | 4.46 |
01:01 ET | 1712 | 4.44 |
01:03 ET | 500 | 4.44 |
01:06 ET | 1977 | 4.44 |
01:08 ET | 500 | 4.44 |
01:12 ET | 600 | 4.44 |
01:14 ET | 763 | 4.44 |
01:15 ET | 300 | 4.45 |
01:17 ET | 68878 | 4.485 |
01:19 ET | 12430 | 4.455 |
01:21 ET | 2180 | 4.49 |
01:24 ET | 1605 | 4.505 |
01:26 ET | 4251 | 4.515 |
01:28 ET | 2280 | 4.505 |
01:30 ET | 100 | 4.5 |
01:32 ET | 4902 | 4.495 |
01:33 ET | 796 | 4.4925 |
01:35 ET | 2100 | 4.4925 |
01:37 ET | 1779 | 4.505 |
01:39 ET | 700 | 4.505 |
01:42 ET | 27018 | 4.535 |
01:44 ET | 10392 | 4.52 |
01:46 ET | 900 | 4.51 |
01:48 ET | 4232 | 4.4901 |
01:50 ET | 26353 | 4.47 |
01:51 ET | 466 | 4.47 |
01:53 ET | 1800 | 4.48 |
01:55 ET | 1100 | 4.495 |
01:57 ET | 3994 | 4.49 |
02:00 ET | 2697 | 4.49 |
02:02 ET | 35916 | 4.485 |
02:04 ET | 385 | 4.49 |
02:06 ET | 1200 | 4.49 |
02:08 ET | 2444 | 4.46 |
02:09 ET | 300 | 4.4625 |
02:11 ET | 1291 | 4.475 |
02:13 ET | 2121 | 4.46 |
02:15 ET | 200 | 4.46 |
02:18 ET | 1322 | 4.45 |
02:20 ET | 2305 | 4.45 |
02:22 ET | 3808 | 4.4546 |
02:24 ET | 311 | 4.45 |
02:26 ET | 300 | 4.4525 |
02:27 ET | 892 | 4.4525 |
02:29 ET | 800 | 4.45 |
02:31 ET | 3132 | 4.435 |
02:33 ET | 2194 | 4.4225 |
02:36 ET | 2400 | 4.43 |
02:38 ET | 100 | 4.435 |
02:40 ET | 300 | 4.44 |
02:42 ET | 100 | 4.43 |
02:44 ET | 1515 | 4.4225 |
02:45 ET | 4811 | 4.4227 |
02:47 ET | 4211 | 4.425 |
02:49 ET | 5257 | 4.42 |
02:51 ET | 2004 | 4.415 |
02:54 ET | 1900 | 4.425 |
02:56 ET | 3225 | 4.445 |
02:58 ET | 6957 | 4.435 |
03:00 ET | 2200 | 4.43 |
03:02 ET | 200 | 4.435 |
03:03 ET | 311 | 4.43 |
03:05 ET | 226 | 4.43 |
03:07 ET | 6091 | 4.445 |
03:09 ET | 737 | 4.45 |
03:12 ET | 2749 | 4.435 |
03:14 ET | 552 | 4.43 |
03:16 ET | 3105 | 4.445 |
03:18 ET | 337 | 4.445 |
03:20 ET | 2497 | 4.425 |
03:21 ET | 1108 | 4.425 |
03:23 ET | 2508 | 4.435 |
03:27 ET | 1113 | 4.435 |
03:30 ET | 326 | 4.4325 |
03:32 ET | 1023 | 4.44 |
03:34 ET | 1000 | 4.43 |
03:36 ET | 9498 | 4.445 |
03:38 ET | 30868 | 4.425 |
03:39 ET | 1652 | 4.425 |
03:41 ET | 764 | 4.43 |
03:43 ET | 1904 | 4.425 |
03:45 ET | 24873 | 4.435 |
03:48 ET | 4145 | 4.43 |
03:50 ET | 1600 | 4.435 |
03:52 ET | 13360 | 4.465 |
03:54 ET | 15844 | 4.435 |
03:56 ET | 16247 | 4.465 |
03:57 ET | 19540 | 4.45 |
03:59 ET | 169955 | 4.47 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.1B | -2.9x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 3.1B | -31.3x | --- |
Xenon Pharmaceuticals Inc | 3.3B | -15.8x | --- |
Janux Therapeutics Inc | 3.2B | -46.4x | --- |
IDEAYA Biosciences Inc | 3.2B | -22.0x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.28 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.